Clinical trials: Body Weight Control
Overweight, Obesity
Can We Achieve 'high-quality' Weight Loss Through Supplementation and Exercise? the TRIM MUSCLE Study
The purpose of this study is to determine whether the combination of two dietary supplements: MUSCLE 5, which contains protein, creatine and vitamin D and TRIM 7, which contains beet extract, caffeine, coenzyme Q10, alpha lipoic…
- Trial name
- NCT05384431
- Testing
- Muscle5 and TRIM7, Mixed exercise
- Where
- Canada
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Exerkine Corporation
Diabetes, Diabetes Mellitus, Type 2
Observational Study in Type 2 Diabetes Treated by an Intensive Insulin Treatment (ICT) Containing Once Daily Levemir® (Insulin Detemir)
This study is conducted in Europe. The aim of this observational study is to gain practical experience with once-daily Levemir administration in type 2 diabetes patients who were previously treated with Insulatard®, Humulin® N…
- Trial name
- LEONCET2 (NCT00657930)
- Testing
- insulin detemir
- Where
- Hungary
- Volunteers
- 2,289 people
- Sponsor
- Novo Nordisk A/S
Overweight or Obesity
The Effect of AMG 133 on Gastric Emptying
The primary objective of the trial is to evaluate the effect of AMG 133 versus placebo on acetaminophen pharmacokinetics (PK), a marker for gastric emptying, in participants living with overweight or obesity.
- Trial name
- NCT07429032
- Testing
- AMG 133, Acetaminophen
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Amgen
Obesity, Overweight
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight and have osteoarthritis (OA) of the knee. The study will lasts about 77 weeks.
- Conditions
- Obesity, Overweight, Osteo Arthritis Knee
- Trial name
- TRIUMPH-4 (NCT05931367)
- Testing
- Retatrutide
- Where
- 49 sites in United States, Australia and 4 more
- Volunteers
- 445 people
- Sponsor
- Eli Lilly and Company
Obesity
Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity
Researchers are doing this study to compare the effects of drugs approved for long-term weight loss combined with an employer-based weight management program with the effects of the weight management program without drugs for…
- Trial name
- NCT03799198
- Testing
- Weight Management Program (WMP), Medication for chronic weight management (Rx)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
A phase 2 study in two parts (A \& B) designed to evaluate the effect of MEDI0382 on Hepatic Glycogen Metabolism in subjects with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT03555994
- Testing
- MEDI0382, Liraglutide
- Where
- 3 sites in Netherlands, Sweden and 1 more
- Volunteers
- 51 people
- Sponsor
- MedImmune LLC
Obesity, Overweight
A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
The aim of this study is to evaluate the efficacy of VRB-101 for body weight reduction compared to placebo in participants who have obesity or overweight with weight-related comorbidities.
- Trial name
- EVOLVE-2 (NCT07281937)
- Testing
- VRB-101
- Where
- 22 sites in United States
- Volunteers
- 206 people
- Sponsor
- Verdiva Bio Dev Limited
Hypercholesterolemia, Cardiovascular Risk Factor
Effect of Totum-070 on Lipid Metabolism in Moderate Hypercholesterolemic Subjects
This clinical study aims to assess the efficacy of TOTUM-070, a mix of 5 plant extracts, on lipid metabolism in moderate hypercholesterolemic subjects.
- Conditions
- Hypercholesterolemia, Cardiovascular Risk Factor, Dyslipidemias, Overweight and Obesity
- Trial name
- HEART (NCT04760951)
- Testing
- TOTUM-070
- Where
- 4 sites in France, Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Valbiotis
Insulin Resistance, Abdominal Obesity
Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal Obesity
The purpose of this study is to demonstrate the efficacy on insulin sensitivity of GFT505 at 80mg/d in male patients with insulin resistance and abdominal obesity. Evaluation will be made using a glucose clamp technique.
- Trial name
- NCT01271777
- Testing
- GFT505 80mg
- Where
- 2 sites in France
- Volunteers
- 22 people
- Sponsor
- Genfit
Diabetes Mellitus, Type 2
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema.
- Trial name
- REIMAGINE 5 (NCT06534411)
- Testing
- Cagrilintide, Semaglutide, Tirzepatide
- Where
- 163 sites in United States, Argentina and 12 more
- Volunteers
- 1,023 people
- Sponsor
- Novo Nordisk A/S
Weight Loss
Effect of Transform Burn on Weight Loss
This study was undertaken to explore the effects of a Thermogenic Composition (TC) composed of dihydrocapsiate, red pepper (Capsicum annuum) fruit extract, citrus (Citrus spp) peel extract, coleus (Coleus forskholi) root extract…
- Trial name
- Transform (NCT06092840)
- Testing
- Transform Burn
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- 4Life Research, LLC
Obesity, Hypertension
A Study of Efficacy and Safety of Topiramate in the Treatment of Obese Patients With Mild to Moderate Essential Hypertension
The purpose of this study is to compare the efficacy and safety of daily topiramate (96mg or 192mg) versus placebo in obese patients with mild to moderate high blood pressure.
- Trial name
- NCT00236665
- Testing
- topiramate
- Volunteers
- 531 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Obesity, Overweight
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.
- Trial name
- TRIUMPH-8 (NCT07232719)
- Testing
- Retatrutide
- Where
- 31 sites in United States, United Kingdom
- Volunteers
- 250 people
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
The purpose of this clinical study is to look at how well a study medicine called cagrilintide helps people living with excess body weight to lose weight.
- Trial name
- RENEW 4 (NCT07745504)
- Testing
- Cagrilintide
- Where
- 36 sites in United States, Greece and 4 more
- Volunteers
- 285 people
- Sponsor
- Novo Nordisk A/S
Nutritional and Metabolic Disease, Overweight
The Acute and Chronic Effects of Fruit Polyphenols on Chronic Disease (PPF)
1. The primary objective is to determine the effect of fruit polyphenols on postprandial lipoprotein triglyceride metabolism after consumption a standard high carbohydrate/fat breakfast meal with a beverage rich in fruit-derived…
- Trial name
- NCT01729949
- Testing
- Active Treatment Beverage
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Obesity
A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HSG4112 in High Doses
1. Study Objective i) To evaluate the safety, tolerability and pharmacokinetic/pharmacodynamic characteristics of HSG4112 after single and multiple oral administration of high doses in healthy subjects.
- Trial name
- NCT05310032
- Testing
- HSG4112
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Glaceum
Non-alcoholic Steatohepatitis (NASH)
A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients
This study is intended to investigate the safety and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD2693, following subcutaneous (SC) administration of multiple ascending doses in participants with…
- Trial name
- NCT04483947
- Testing
- AZD2693
- Where
- 16 sites in United States
- Volunteers
- 74 people
- Sponsor
- AstraZeneca
Obesity
A Trial of HRS-5817 in Obese Participants
The purpose of this study is to assess safety, PK, Pharmacodynamic and immunogenicity profile of a single dose of HRS-5817 in obese participants
- Trial name
- NCT07238647
- Testing
- HRS-5817
- Where
- Australia
- Volunteers
- 40 people
- Sponsor
- Atridia Pty Ltd.
Obesity, Overweight, or Chronic Weight Management
A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
This study is a randomized, double-blind, placebo-controlled, dose-range finding study of the efficacy, safety, tolerability, PK, and PD of multiple doses of aleniglipron in participants living with overweight or obesity with at…
- Trial name
- ACCESS (NCT06693843)
- Testing
- Aleniglipron
- Where
- 39 sites in United States
- Volunteers
- 230 people
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Obesity, Dyslipidemias
European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemia
Primary : To determine the effect of Rimonabant 20 mg on changes in, HDL-Cholesterol (HDL-C), triglyceride levels over a period of 12 months when prescribed with a mild hypocaloric diet in abdominally obese patients with…
- Trial name
- ETERNAL (NCT00412698)
- Testing
- rimonabant
- Where
- 15 sites in Czechia, Finland and 13 more
- Volunteers
- 645 people
- Sponsor
- Sanofi